Evofem Biosciences, Inc. is a San Diego-based commercial-stage biopharmaceutical company focused on women's sexual and reproductive health. Its primary product, PHEXX (lactic acid, citric acid and potassium bitartrate vaginal gel), is the first FDA-approved non-hormonal prescription contraceptive vaginal gel, launched in September 2020. The company also commercializes SOLOSEC (secnidazole 2g oral granules), a single-dose oral antimicrobial for bacterial vaginosis and trichomoniasis, acquired in July 2024 and relaunched in November 2024.
Q2 FY2026 — expected 2026-08-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-11 | 2025-12-31 | 0001493152-26-009686 | EDGAR | 131K words |
| 2025-03-24 | 2024-12-31 | 0001641172-25-000188 | EDGAR | — |
| 2024-03-27 | 2023-12-31 | 0001493152-24-011404 | EDGAR | — |
| 2023-04-27 | 2022-12-31 | 0001618835-23-000023 | EDGAR | — |
| 2022-03-10 | 2021-12-31 | 0001618835-22-000057 | EDGAR | — |
| 2021-03-04 | 2020-12-31 | 0001618835-21-000040 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001618835-20-000047 | EDGAR | — |
| 2019-03-01 | 2018-12-31 | 0001618835-19-000031 | EDGAR | — |
| 2018-02-26 | 2017-12-31 | 0001564590-18-003259 | EDGAR | — |
| 2017-03-23 | 2016-12-31 | 0001564590-17-005093 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001493152-25-022275 | EDGAR | 44K words |
| 2025-08-14 | 2025-06-30 | 0001641172-25-023741 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001641172-25-010529 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001493152-24-046060 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001493152-24-031846 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001493152-24-019428 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001493152-23-040764 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001493152-23-028671 | EDGAR | — |
| 2023-06-16 | 2023-03-31 | 0001493152-23-021701 | EDGAR | — |
| 2023-01-06 | 2022-09-30 | 0001618835-23-000001 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001618835-22-000166 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001618835-22-000110 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-19 | 0001493152-26-011613 | EDGAR | 1K words |
| 2026-03-11 | 0001493152-26-009689 | EDGAR | — |
| 2026-01-12 | 0001493152-26-001886 | EDGAR | — |
| 2025-11-26 | 0001493152-25-025172 | EDGAR | — |
| 2025-11-13 | 0001493152-25-022318 | EDGAR | — |
| 2025-10-20 | 0001493152-25-018687 | EDGAR | — |
| 2025-10-17 | 0001493152-25-018454 | EDGAR | — |
| 2025-08-26 | 0001641172-25-025530 | EDGAR | — |
| 2025-08-14 | 0001641172-25-023740 | EDGAR | — |
| 2025-07-02 | 0001641172-25-017563 | EDGAR | — |
329 total filings indexed. 297 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001618835 |
| Ticker | EVFM |
| Exchange | OTC |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Headquarters | San Diego, California |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report